Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BeiGene, Ltd. - American Depositary Shares (NQ: BGNE )

184.71 UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BeiGene, Ltd. - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
What's Happening With Beigene Shares During Wednesday's Session
Beigene Ltd (NASDAQ: BGNE) shares are trading lower by 3.41% to $185.03 Wednesday morning on downward momentum following Tuesday weakness. 
Via Benzinga
BGNE INVESTOR NEWS: ROSEN, A LEADING LAW FIRM, Encourages BeiGene, Ltd. Investors to Inquire About Securities Class Action Investigation – BGNE
From The Rosen Law Firm PA
Via GlobeNewswire
Kirby McInerney LLP Continues Investigation of Shareholder Claims Against BeiGene, Ltd. (BGNE)
From Kirby McInerney LLP
Via Business Wire
BGNE LOSS ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages BeiGene, Ltd. Investors to Inquire About Securities Class Action Investigation - BGNE
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
Recap: BeiGene Q1 Earnings
Via Benzinga
BeiGene's Tislelizumab/Chemo Combo Hits Primary Goal In Gastric Cancer Study
Via Benzinga
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against BeiGene, Ltd. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
BGNE INVESTOR NEWS: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages BeiGene, Ltd. Investors to Inquire About Securities Class Action Investigation – BGNE
From The Rosen Law Firm, P.A.
Via Business Wire
AbbVie Says BeiGene's Flagship Blood Cancer Drug Infringes Imbruvica Patent
BeiGene Ltd (NASDAQ: BGNE) says it is aware that Pharmacyclics LLC has filed a complaint alleging that BeiGene's blood cancer therapy Brukinsa (zanubrutinib) infringes a Pharmacyclics  
Via Benzinga
BeiGene to Vigorously Defend Patent Infringement Allegations by Pharmacyclics
From BeiGene
Via Business Wire
Why MicroVision Shares Are Trading Higher By 28%; Here Are 20 Stocks Moving Premarket
Gainers EdtechX Holdings Acquisition Corp. II (NASDAQ: EDTX) shares gained 139.8% to $26.54 in pre-market trading. 
Via Benzinga
Gambling.com, Editas Medicine And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
BeiGene Highlights Promising Data from Blood Cancer Portfolio and Pipeline at the European Hematology Association Hybrid Congress
From BeiGene
Via Business Wire
BRUKINSA® Approved in Canada for the Treatment of Chronic Lymphocytic Leukemia
From BeiGene, Ltd.
Via Business Wire
BeiGene Presentations at the 2023 ASCO Annual Meeting Reinforce Promise Across Oncology Portfolio
From BeiGene
Via Business Wire
Mirati's Sitravatinib Flunks Phase 3 Combo Therapy Study In Type Of Lung Cancer Setting
Via Benzinga
BeiGene to Present at Upcoming Investor Conferences
From BeiGene
Via Business Wire
Immix Biopharma's Subsidiary Says Investigational CAR T Therapy Shows 100% Response Rate In Amyloidosis
Immix Biopharma Inc's (NASDAQ: IMMX) subsidiary Nexcella Inc announced updated AL Amyloidosis clinical data from its ongoing Phase 1b/2a NEXICART-1 study of its BCMA-targeted chimeric antigen receptor... 
Via Benzinga
The Max Foundation, BeiGene, and the BeiGene Foundation Announce Collaboration to Advance Health Equity by Providing Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries
From BeiGene
Via Business Wire
BeiGene Receives New Approvals for BRUKINSA® (zanubrutinib) in China
From BeiGene
Via Business Wire
BeiGene Reports First Quarter 2023 Financial Results and Corporate Developments
From BeiGene, Ltd.
Via Business Wire
What's Going On With Immix Biopharma Stock Today
Immix Biopharma Inc (NASDAQ: IMMX) announced early interim data from IMMINENT-01 Phase 1b/2a trial combining tissue-specific therapeutic IMX-110 with BeiGene Ltd (NYSE: BGNE) / Novartis AG' 
Via Benzinga
BeiGene to Highlight Broad Oncology Portfolio at the 2023 ASCO Annual Meeting
From BeiGene
Via Business Wire
3 Top Biotech Stocks Defying the Bear Market
All three companies have therapies with strong sales potential. 
Via The Motley Fool
BeiGene Announces Goals Focused on Sustainable Growth and Workforce Diversity in New ESG Report
From BeiGene
Via Business Wire
BeiGene Announces Positive Phase 3 Tislelizumab Trial in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
From BeiGene
Via Business Wire
7 Biotech Stocks That Could Cure Your Portfolio Woes
If you want to revitalize your portfolio with some exciting opportunities, these biotech stocks to buy might fit the bill. 
Via InvestorPlace
BeiGene and SpringWorks Present Clinical Data on Lifirafenib, in Combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023
From BeiGene, Ltd.
Via Business Wire
SpringWorks and BeiGene Present Clinical Data on Lifirafenib, in combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.